
    
      This study will help to understand the efficacy of Nivolumab in the real world setting within
      the SPANISH expanded access programme.

      The main objective of this study is to evaluate nivolumab efficacy in terms of Overall
      Survival (OS), Progression Free Survival (PFS), Overall Response Rate (ORR) and safety in the
      clinical practice.

      The efficacy variables will be assessed for patients (squamous vs non-squamous) who received
      second line therapies or third lines and subsequent lines and also, long responders will be
      evaluated.
    
  